Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Graft Polymer (UK) PLC ( (GB:SVNS) ).
Solvonis Therapeutics plc has initiated an AI-supported drug discovery program centered on its proprietary CNS compound library, acquired from Awakn Life Sciences Corp. This program aims to accelerate the identification and optimization of high-value development candidates for neuropsychiatric conditions such as depression and stimulant use disorders. The initiative, led by Professor David Nutt, enhances Solvonis’ R&D pipeline, complementing existing programs and reflecting the company’s strategy to combine innovation with rigorous science to address significant mental health challenges.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the London Stock Exchange, Solvonis targets high-burden neuropsychiatric conditions with significant unmet need, including Alcohol Use Disorder and Post-Traumatic Stress Disorder.
Average Trading Volume: 22,961,744
Technical Sentiment Signal: Sell
Current Market Cap: £8.42M
Find detailed analytics on SVNS stock on TipRanks’ Stock Analysis page.